The FDA approved a much-anticipated once-daily HIV medication from Gilead Sciences, ratcheting up its battle against GlaxoSmithKline for market share. Glaxo’s response? A lawsuit.
from Forbes Real Time https://www.forbes.com/sites/johannabennett/2018/02/08/gilead-vs-glaxo-see-you-in-court/
via IFTTT
No comments:
Post a Comment